Perfil
Jean-François Le Bigot is currently the Chief Executive Officer at Oncovita SAS and the Chairman at Ginko Invest.
He was previously the Director at Affluent Medical SA from 2020 to 2022.
Cargos activos de Jean-François Le Bigot
Empresas | Cargo | Inicio |
---|---|---|
Oncovita
Oncovita BiotechnologyHealth Technology Oncovita SAS is a biotech company based in Paris, France. Oncovita is developing a virus-derived vaccine technology to treat multiple types of cancers. The technology utilizes the natural anti-cancer and immunogenic properties of a harmless vaccine, making it a versatile platform. The MeasovirTM platform, derived from the safe and highly immunogenic measles vaccine virus, has clinically proven oncolytic potential and specifically targets and destroys cancer cells. The French company was founded in 2015 by Frédéric Tangy and is currently led by CEO Jean-François Le Bigot. | Director Ejecutivo | - |
Ginko Invest
Ginko Invest Financial ConglomeratesFinance Ginko Invest operates as an investment firm. | Presidente | - |
Antiguos cargos conocidos de Jean-François Le Bigot.
Empresas | Cargo | Fin |
---|---|---|
AFFLUENT MEDICAL | Director/Miembro de la Junta | 19/01/2022 |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
AFFLUENT MEDICAL | Health Technology |
Empresas privadas | 2 |
---|---|
Ginko Invest
Ginko Invest Financial ConglomeratesFinance Ginko Invest operates as an investment firm. | Finance |
Oncovita
Oncovita BiotechnologyHealth Technology Oncovita SAS is a biotech company based in Paris, France. Oncovita is developing a virus-derived vaccine technology to treat multiple types of cancers. The technology utilizes the natural anti-cancer and immunogenic properties of a harmless vaccine, making it a versatile platform. The MeasovirTM platform, derived from the safe and highly immunogenic measles vaccine virus, has clinically proven oncolytic potential and specifically targets and destroys cancer cells. The French company was founded in 2015 by Frédéric Tangy and is currently led by CEO Jean-François Le Bigot. | Health Technology |
- Bolsa de valores
- Insiders
- Jean-François Le Bigot